ISC 2026

Conference

Asundexian Associated with an Impressive 26% Reduction in Recurrent Stroke Without Increased Bleeding. The OCEANIC-STROKE trial

Asundexian is a direct, potent small molecule inhibitor of Factor XIa (FXIa).…